118 related articles for article (PubMed ID: 12716484)
1. Serial analysis of soluble intercellular adhesion molecule-1 level in relapsing-remitting multiple sclerosis patients during IFN-beta1b treatment.
Kilinc M; Saatci-Cekirge I; Karabudak R
J Interferon Cytokine Res; 2003 Mar; 23(3):127-33. PubMed ID: 12716484
[TBL] [Abstract][Full Text] [Related]
2. Serum soluble intercellular adhesion molecule-I in MS: relation to clinical and Gd-MRI activity and to rIFN beta-Ib treatment.
Trojano M; Avolio C; Ruggieri M; Defazio G; Giuliani F; Paolicelli D; Livrea P
Mult Scler; 1998 Jun; 4(3):183-7. PubMed ID: 9762671
[TBL] [Abstract][Full Text] [Related]
3. Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings.
Trojano M; Avolio C; Simone IL; Defazio G; Manzari C; De Robertis F; Calò A; Livrea P
Neurology; 1996 Dec; 47(6):1535-41. PubMed ID: 8960741
[TBL] [Abstract][Full Text] [Related]
4. Interferon-beta 1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis.
Kraus J; Bauer R; Chatzimanolis N; Engelhardt B; Tofighi J; Bregenzer T; Kuehne BS; Stolz E; Blaes F; Morgen K; Traupe H; Kaps M; Oschmann P
J Neurol; 2004 Apr; 251(4):464-72. PubMed ID: 15083294
[TBL] [Abstract][Full Text] [Related]
5. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.
Trojano M; Avolio C; Liuzzi GM; Ruggieri M; Defazio G; Liguori M; Santacroce MP; Paolicelli D; Giuliani F; Riccio P; Livrea P
Neurology; 1999 Oct; 53(7):1402-8. PubMed ID: 10534242
[TBL] [Abstract][Full Text] [Related]
6. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
Chatzimanolis N; Kraus J; Bauer R; Engelhardt B; Bregenzer T; Kuehne BS; Tofighi J; Laske C; Stolz E; Blaes F; Voigt K; Traupe H; Kaps M; Oschmann P
Acta Neurol Scand; 2004 Dec; 110(6):377-85. PubMed ID: 15527450
[TBL] [Abstract][Full Text] [Related]
7. Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis.
Rieckmann P; Altenhofen B; Riegel A; Kallmann B; Felgenhauer K
Mult Scler; 1998 Jun; 4(3):178-82. PubMed ID: 9762670
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal sICAM-1 production in multiple sclerosis--correlation with triple dose Gd-DTPA MRI enhancement and IgG index.
Acar G; Idiman F; Kirkali G; Ozakbaş S; Oktay G; Cakmakçi H; Idiman E
J Neurol; 2005 Feb; 252(2):146-50. PubMed ID: 15729518
[TBL] [Abstract][Full Text] [Related]
9. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
Jensen J; Krakauer M; Sellebjerg F
Cytokine; 2005 Jan; 29(1):24-30. PubMed ID: 15579375
[TBL] [Abstract][Full Text] [Related]
10. Soluble intercellular adhesion molecule-I (sICAM-I) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system.
Trojano M; Avolio C; Ruggieri M; De Robertis F; Giuliani F; Paolicelli D; Livrea P
Mult Scler; 1998 Feb; 4(1):39-44. PubMed ID: 9532592
[TBL] [Abstract][Full Text] [Related]
11. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
Alexander JS; Harris MK; Wells SR; Mills G; Chalamidas K; Ganta VC; McGee J; Jennings MH; Gonzalez-Toledo E; Minagar A
Mult Scler; 2010 Jul; 16(7):801-9. PubMed ID: 20621951
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging.
Giovannoni G; Lai M; Thorpe J; Kidd D; Chamoun V; Thompson AJ; Miller DH; Feldmann M; Thompson EJ
Neurology; 1997 Jun; 48(6):1557-65. PubMed ID: 9191766
[TBL] [Abstract][Full Text] [Related]
13. Serum endothelial adhesion molecules levels correlate with lesion burden in multiple sclerosis patients treated with interferon beta-1b.
Dinca LP; Lucas M; Zayas MD; Muñoz MA; Garcia Moreno JM; Navarro G; Gata JM; Solano F; Izquierdo G
Neurochem Int; 2000 May; 36(6):549-53. PubMed ID: 10762092
[TBL] [Abstract][Full Text] [Related]
14. Effects of rIFN-beta-1b on serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells.
Trojano M; Defazio G; Avolio C; Paolicelli D; Giuliani F; Giorelli M; Livrea P
J Neurovirol; 2000 May; 6 Suppl 2():S47-51. PubMed ID: 10871785
[TBL] [Abstract][Full Text] [Related]
15. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
Carmona O; Casado V; Moral E; Alonso-Magdalena L; Martínez-Yélamos A; Martínez-Yélamos S; Martín-Ozaeta G; Arbizu T
Eur Neurol; 2008; 60(6):279-84. PubMed ID: 18824855
[TBL] [Abstract][Full Text] [Related]
16. Short communication: treatment of relapsing-remitting multiple sclerosis 96 patients with IFN-beta 1b: results of a 6-year follow-up.
Bencsik K; Füvesi J; Fricska-Nagy Z; Rajda C; Losonczi E; Török M; Vécsei L
J Interferon Cytokine Res; 2006 Feb; 26(2):96-100. PubMed ID: 16487029
[TBL] [Abstract][Full Text] [Related]
17. Soluble CD8 and ICAM-1 in serum and CSF of MS patients treated with 6-methylprednisolone.
Franciotta D; Piccolo G; Zardini E; Bergamaschi R; Cosi V
Acta Neurol Scand; 1997 May; 95(5):275-9. PubMed ID: 9188901
[TBL] [Abstract][Full Text] [Related]
18. Serum Levels of Biomarkers of Immune Activation and Associations With Neurological Impairment in Relapsing-Remitting Multiple Sclerosis Patients During Remission.
Witkowska AM; Socha K; Kochanowicz J; Karpińska E; Jakoniuk M; Zujko ME; Wilkiel M; Borawska MH; Mariak Z
Biol Res Nurs; 2016 Jan; 18(1):113-9. PubMed ID: 25911236
[TBL] [Abstract][Full Text] [Related]
19. [Clinical course and changes of soluble interleukin-2 receptor and soluble forms of intercellular adhesion molecule-1 (ICAM-1) in serum of multiple sclerosis patients].
Bilińska M; Frydecka I; Podemski R
Neurol Neurochir Pol; 2001; 35(1):47-56. PubMed ID: 11464716
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis.
Antonetti F; Finocchiaro O; Mascia M; Terlizzese MG; Jaber A
J Interferon Cytokine Res; 2002 Dec; 22(12):1181-4. PubMed ID: 12581490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
